Research ExplorerPublicationsClinical impact of antibody formation to botulinum toxin A i...

Clinical impact of antibody formation to botulinum toxin A in children.

Standard

Clinical impact of antibody formation to botulinum toxin A in children. / Herrmann, Jochen; Geth, Katrin; Mall, Volker; Bigalke, Hans; Jürgen, Schulte Mönting; Linder, Michaela; Kirschner, Jan; Berweck, Steffen; Korinthenberg, Rudolf; Heinen, Florian; Fietzek, Urban M.

In: ANN NEUROL, Vol. 55, No. 5, 5, 2004, p. 732-735.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Herrmann, J, Geth, K, Mall, V, Bigalke, H, Jürgen, SM, Linder, M, Kirschner, J, Berweck, S, Korinthenberg, R, Heinen, F & Fietzek, UM 2004, 'Clinical impact of antibody formation to botulinum toxin A in children.', ANN NEUROL, vol. 55, no. 5, 5, pp. 732-735. <http://www.ncbi.nlm.nih.gov/pubmed/15122715?dopt=Citation>

APA

Herrmann, J., Geth, K., Mall, V., Bigalke, H., Jürgen, S. M., Linder, M., Kirschner, J., Berweck, S., Korinthenberg, R., Heinen, F., & Fietzek, U. M. (2004). Clinical impact of antibody formation to botulinum toxin A in children. ANN NEUROL, 55(5), 732-735. [5]. http://www.ncbi.nlm.nih.gov/pubmed/15122715?dopt=Citation

Vancouver

Herrmann J, Geth K, Mall V, Bigalke H, Jürgen SM, Linder M et al. Clinical impact of antibody formation to botulinum toxin A in children. ANN NEUROL. 2004;55(5):732-735. 5.

Bibtex

@article{d8d943c14f3649bfaa723aeba1354368,
title = "Clinical impact of antibody formation to botulinum toxin A in children.",
abstract = "We studied the clinical impact of neutralizing antibodies to botulinum toxin A that occurred during long-term treatment of children between 1993 and 2001. Antibodies were found in high titers in 35 of 110 (31.8%) samples from individual patients. Antibody formation correlated with secondary nonresponse (p <0.001). The most significant risk factors for antibody formation were the frequency of treatments (p = 0.0001) and the injection of a higher weight-adapted maximum dose per treatment (p = 0.001).",
author = "Jochen Herrmann and Katrin Geth and Volker Mall and Hans Bigalke and J{\"u}rgen, {Schulte M{\"o}nting} and Michaela Linder and Jan Kirschner and Steffen Berweck and Rudolf Korinthenberg and Florian Heinen and Fietzek, {Urban M}",
year = "2004",
language = "Deutsch",
volume = "55",
pages = "732--735",
journal = "ANN NEUROL",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

RIS

TY - JOUR

T1 - Clinical impact of antibody formation to botulinum toxin A in children.

AU - Herrmann, Jochen

AU - Geth, Katrin

AU - Mall, Volker

AU - Bigalke, Hans

AU - Jürgen, Schulte Mönting

AU - Linder, Michaela

AU - Kirschner, Jan

AU - Berweck, Steffen

AU - Korinthenberg, Rudolf

AU - Heinen, Florian

AU - Fietzek, Urban M

PY - 2004

Y1 - 2004

N2 - We studied the clinical impact of neutralizing antibodies to botulinum toxin A that occurred during long-term treatment of children between 1993 and 2001. Antibodies were found in high titers in 35 of 110 (31.8%) samples from individual patients. Antibody formation correlated with secondary nonresponse (p <0.001). The most significant risk factors for antibody formation were the frequency of treatments (p = 0.0001) and the injection of a higher weight-adapted maximum dose per treatment (p = 0.001).

AB - We studied the clinical impact of neutralizing antibodies to botulinum toxin A that occurred during long-term treatment of children between 1993 and 2001. Antibodies were found in high titers in 35 of 110 (31.8%) samples from individual patients. Antibody formation correlated with secondary nonresponse (p <0.001). The most significant risk factors for antibody formation were the frequency of treatments (p = 0.0001) and the injection of a higher weight-adapted maximum dose per treatment (p = 0.001).

M3 - SCORING: Zeitschriftenaufsatz

VL - 55

SP - 732

EP - 735

JO - ANN NEUROL

JF - ANN NEUROL

SN - 0364-5134

IS - 5

M1 - 5

ER -